VSTM - ベラステム (Verastem Inc.) ベラステム

 VSTMのチャート


 VSTMの企業情報

symbol VSTM
会社名 Verastem Inc (ベラステム)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ヴェラステム(ベラステム)(Verastem Inc.)は生物製薬会社である。同社は、癌幹細胞(CSC)を標的とする小分子薬及びコンパニオン診断薬の発見及び開発に注力する。同社の先進的な製品候補は小分子薬「VS-507」である。同社の科学関係の共同設立者は「VS-507」を乳癌幹細胞を殺すための候補薬として同定した。平成23年11月3日現在、同社は「VS-507」を乳癌の潜在的な治療薬として臨床試験により評価している。   ベラステムは米国のバイオ医薬品企業。癌治療に焦点を当て、癌幹細胞を殺す薬剤の開発、独自コンパニオン診断の開発を行う。最新プログラムは焦点接着キナ―ゼやPI3K/mTORシグナル伝達経路治療剤など。VS-6063、VS-4718、VS-5584の製品候補を手掛け、前臨床・臨床試験にて中皮腫、卵巣癌、肺癌などの癌治療法としての評価を行う。   Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
本社所在地 117 Kendrick Street Suite 500 Needham MA 02494 USA
代表者氏名 Robert Forrester Robert Forrester
代表者役職名 President Chief Executive Officer
電話番号 +1 781-292-4200
設立年月日 40391
市場名 NASDAQ National Market System
ipoyear 2012年
従業員数 69人
url www.verastem.com
nasdaq_url https://www.nasdaq.com/symbol/vstm
adr_tso
EBITDA EBITDA(百万ドル) -79.08600
終値(lastsale) 6.69
時価総額(marketcap) 492332239.47
時価総額 時価総額(百万ドル) 458.47980
売上高 売上高(百万ドル) 10.00000
企業価値(EV) 企業価値(EV)(百万ドル) 314.69180
当期純利益 当期純利益(百万ドル) -80.77800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Verastem Inc revenues increased from $0K to $10M. Net loss increased 49% to $39.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative increase from $9.2M to $25.6M (expense) Research and development increase of 34% to $23.3M (expense).

 VSTMのテクニカル分析


 VSTMのニュース

   Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up  2020/01/09 08:00:00 Zacks Investment Research
Verastem (VSTM) enters into an agreement with Chugai Pharmaceutical to gain worldwide rights to the latter's RAF/MEK inhibitor, CH5126766, for $3 million in upfront payment.
   Verastem Oncology Announces Submission of a Marketing Authorization Application to the European Medicines Agency for COPIKTRA® (duvelisib)  2019/11/25 12:00:00 Business Wire
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeki
   The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval  2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.
   The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing  2019/11/14 13:07:04 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 13.) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bausch Health Companies Inc (NYSE: BHC ) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) (reacted to its third-quarter results) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) (reacted to its third-quarter results) IGM Biosciences Inc (NASDAQ: IGMS ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Opiant Pharmaceuticals Inc (NASDAQ: OPNT ) ( reported an unexpected profit for its third quarter) Recro Pharma Inc (NASDAQ: REPH ) Seattle Genetics, Inc. (NASDAQ: SGEN ): filed an arbitration demand to settle dispute with DAIICHI SANKYO/S ADR (OTC: DSNKY ).
   The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher  2019/11/13 12:10:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) Crispr Therapeutics AG (NASDAQ: CRSP ) Diplomat Pharmacy Inc (NYSE: DPLO )( warned of going concern risk) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) XOMA Corp (NASDAQ: XOMA ) Zai Lab Ltd (NASDAQ: ZLAB ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov.
   Verastem Oncology Announces Submission of a Marketing Authorization Application to the European Medicines Agency for COPIKTRA® (duvelisib)  2019/11/25 12:00:00 Business Wire
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeki
   The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval  2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.
   The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing  2019/11/14 13:07:04 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 13.) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bausch Health Companies Inc (NYSE: BHC ) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) (reacted to its third-quarter results) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) (reacted to its third-quarter results) IGM Biosciences Inc (NASDAQ: IGMS ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Opiant Pharmaceuticals Inc (NASDAQ: OPNT ) ( reported an unexpected profit for its third quarter) Recro Pharma Inc (NASDAQ: REPH ) Seattle Genetics, Inc. (NASDAQ: SGEN ): filed an arbitration demand to settle dispute with DAIICHI SANKYO/S ADR (OTC: DSNKY ).
   The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher  2019/11/13 12:10:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) Crispr Therapeutics AG (NASDAQ: CRSP ) Diplomat Pharmacy Inc (NYSE: DPLO )( warned of going concern risk) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) XOMA Corp (NASDAQ: XOMA ) Zai Lab Ltd (NASDAQ: ZLAB ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov.
   Verastem's (VSTM) Copiktra Gets Orphan Drug Designation  2019/10/08 09:02:00 Zacks Investment Research
Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ベラステム VSTM Verastem Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)